Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology. In vivo study data showed that oral MAT2203 effectively targeted melanoma tumors and was associated with none of the toxicity observed with conventional IV-docetaxel. The Company believes its cash position is sufficient to fund planned operations through the third quarter of 2024.